Does replacement of vitamin D reduce the symptom scores and improve quality of life in patients with chronic urticaria?


Topal I. O., Kocaturk E., Gungor S., Durmuscan M., Sucu V., Yildirmak S.

JOURNAL OF DERMATOLOGICAL TREATMENT, cilt.27, sa.2, ss.163-166, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.3109/09546634.2015.1079297
  • Dergi Adı: JOURNAL OF DERMATOLOGICAL TREATMENT
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.163-166
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: Vitamin D plays a key role in the immune responses generated by lymphocytes and antigen-presenting cells. Decreased vitamin 25-hydroxyvitamin D (25(OH)D) levels have been implicated in several allergic disorders and association between 25(OH)D levels and chronic urticaria (CU) symptom scores has been evaluated in a few studies. This study was performed to assess the effects of vitamin D supplementation on the symptoms and quality of life scores in chronic spontaneous urticaria (CSU) and to vitamin D levels in CSU patients in comparison with controls. Patients and methods: Fifty-eight CSU patients and forty-five controls were included in the study. The patients were divided into two groups according to severity of the disease; as mild/moderate and severe urticaria. Serum 25-hydroxyvitamin D (25(OH)D) concentrations were measured in serum of CSU patients and compared with the control groups. In patients with 25(OH)D concentrations lower than 30 mu g/L, 300000IU/month of vitamin D3 supplementation was added to standard therapy. The clinical improvement was evaluated after 3 months with urticaria activity score (UAS4) and Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). Results: Serum 25(OH)D concentration was significantly lower in CSU group compared to healthy subjects (p<0.001). The prevalence of vitamin D deficiency (<20 (mu g/L) and insufficiency (<30 mu g/L) was significantly higher in CSU patients than control groups. In addition, 25(OH)D concentrations were significantly lower in both mild-moderate and severe CSU patients than those of the controls (p=0.011 and p<0.001, respectively). Ninety eight percent of patients (25(OH)D<30 mu g/L) were treated with vitamin D3 (300000IU/month) supplementation, and after 12 weeks, these patients showed significant improvements in UAS4 and CU-Q2oL scores. Conclusion: This study support the contributing and beneficial effects of vitamin D in the treatment of CU. Replacement of vitamin D may provide improvement in both the severity of symptoms and the quality of life scores in these patients.